Home › Funds › SHENKMAN CAPITAL MANAGEMENT INC › TVTX
SHENKMAN CAPITAL MANAGEMENT INC position in TVTX
TRAVERE THERAPEUTICS INC · Health Care
SHENKMAN CAPITAL MANAGEMENT INC reported holding 2,250,000 shares of TVTX (TRAVERE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$2.7M, representing 0.51% of its reported portfolio and ranking #48 among its reported holdings. SHENKMAN CAPITAL MANAGEMENT INC has disclosed TVTX holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How SHENKMAN CAPITAL MANAGEMENT INC's TVTX position evolved
SHENKMAN CAPITAL MANAGEMENT INC first disclosed a stake in TVTX in Q1 2025 at 6,874,000 shares (US$7.2M). The position peaked in Q1 2026 at 9,662,000 shares, worth US$12.4M. Across 6 filings, SHENKMAN CAPITAL MANAGEMENT INC increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,250,000 shares valued at US$2.7M — a reduction of -7,412,000 shares quarter over quarter.. Notable position changes include a 45% increase in Q1 2026 (shares rose 91% over the following quarter), a 77% trim in Q2 2026 (shares rose 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 6.87M | $7.16M | New |
| Q2 2025 | 5.64M | $5.68M | Reduce |
| Q3 2025 | 6.24M | $7.22M | Add |
| Q4 2025 | 6.66M | $9.75M | Add |
| Q1 2026 | 9.66M | $12.44M | Add |
| Q2 2026 | 2.25M | $2.69M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TVTX and 13F data
TVTX (TRAVERE THERAPEUTICS INC) is a Health Care company. 57 other funds we track also report a position in TVTX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$213.2M), Rock Springs Capital Management LP (US$123.8M), Kynam Capital Management, LP (US$113.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TVTX
- PERCEPTIVE ADVISORS LLC 3.75M sh · $213.18M · Q2 2026
- Rock Springs Capital Management LP 2.18M sh · $123.79M · Q2 2026
- Kynam Capital Management, LP 2.00M sh · $113.62M · Q2 2026
- Stephens Investment Management Group LLC 1.88M sh · $106.54M · Q2 2026
- EMERALD ADVISERS, LLC 1.60M sh · $90.95M · Q2 2026
- MPM BioImpact LLC 1.12M sh · $63.78M · Q2 2026
- Context Capital Management, LLC 50.50M sh · $59.46M · Q2 2026
- EMERALD MUTUAL FUND ADVISERS TRUST 1.03M sh · $58.63M · Q2 2026
- Eversept Partners, LP 798.97K sh · $45.39M · Q2 2026
- Polar Asset Management Partners Inc. 30.50M sh · $35.91M · Q2 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 28.00M sh · $32.96M · Q2 2026
- ARMISTICE CAPITAL, LLC 500.00K sh · $28.41M · Q2 2026
More on SHENKMAN CAPITAL MANAGEMENT INC
FAQ
How long has SHENKMAN CAPITAL MANAGEMENT INC held TVTX?
SHENKMAN CAPITAL MANAGEMENT INC has disclosed TVTX holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
What is SHENKMAN CAPITAL MANAGEMENT INC's current position in TVTX?
As of Q2 2026, SHENKMAN CAPITAL MANAGEMENT INC holds 2.25M shares of TVTX (TRAVERE THERAPEUTICS INC), valued at $2.69M, representing 0.51% of its reported portfolio and ranking #48.
Has SHENKMAN CAPITAL MANAGEMENT INC been buying or selling TVTX?
In the latest 13F filing (Q2 2026), SHENKMAN CAPITAL MANAGEMENT INC reduced its position in TVTX. The position peaked in Q1 2026 at 9.66M shares.
Which other funds hold TVTX?
Other major institutional holders of TVTX include PERCEPTIVE ADVISORS LLC, Rock Springs Capital Management LP, Kynam Capital Management, LP, among 57 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.